Regeneron Pharmaceuticals, Inc.

REGN.VI·Vienna·Healthcare
Compare
830.80−22.90 (−2.68%)today
As of Nov 5, 11:00 AM CET · May be delayed up to 15 min · EUR

Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.

Key statistics

Previous close853.70
Open829.80
Day range829.80830.80
52-week range512.70867.10
Off day high0.00%
Off 52-week high−4.19%
Volume0.00
Avg. volume (3M)0.00
Market cap85.94B
EPS (TTM)38.94
Forward P/E—
P/E ratio (TTM)21.34
Dividend yield0.39% (3.36)
Beta (5Y)0.15
Shares outstanding101.63M
Short interest—
Earnings dateOct 30, 2026 (est.)
Analyst target—
Profit margin27.87%

Against its peers

Compare in full ›
REGN.VI 9995.HK ROIV 4593.T RPRX 214450.KQ
Market cap 85.94B 40.23B 27.61B 33.08B 39.04B 2.34T
P/E (TTM) 21.3 6.1 — 235.6 44.2 —
Forward P/E — 46.7 -27.5 -8.6 11.6 —
Price/book 2.8 3.8 6.5 3.8 4.5 —
Dividend yield 0.39% — — — 1.39% 1.66%
1-year change +57.43% −19.94% +85.85% −47.95% +65.67% −56.00%
Today −2.68% +1.49% +6.08% −3.54% +1.75% +0.67%

The closest companies by business and industry (Biotechnology). Prices may be delayed up to 20 min.

Latest news

All REGN.VI news ›
The Motley Fool·Positive

Regeneron: 3 Key Takeaways for Long-Term Investors

An early-stage liver disease therapy cut fat by 70% in just 12 weeks, signaling the genetics engine's potential to fuel growth beyond current blockbusters. On its third quarter of 2026 earnings call, held on Oct. 30, 2026, Regeneron (REGN…

The Globe and Mail·

Regeneron (REGN) Receives a Hold from RBC Capital

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades. RBC Capital analyst Brian Abrahams maintained a Hold rating on Regeneron on October 27 and set a price target of…

@_AlphaStreet·Positive

Regeneron Pharmaceuticals Releases Q3 2026 Financial Results

Regeneron Pharmaceuticals, Inc. The post Regeneron Pharmaceuticals Releases Q3 2026 Financial Results first appeared on Alphastreet. AlphaStreet Newsdesk powered by AlphaStreet Intelligence Regeneron Pharmaceuticals, Inc. delivered a…

Seeking Alpha·Positive

Regeneron Is Just Getting Started

Regeneron enters a new growth cycle after a strong Q3, with Dupixent, Eylea HD, and pipeline momentum boosting the outlook. Read this analysis on REGN here. - Regeneron delivered a standout Q3, with net sales up 36% year-over-year to $5.1…

From the 4Search news index, newest first.

In the news

336mentions in 30 days
61with it in the headline
Positivesentiment

Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 120 articles, not a forecast.

Market data is provided for information only and comes from free public sources. Prices may be delayed up to 15 minutes; data may be incomplete or inaccurate. Nothing on this page is investment advice or a recommendation to buy or sell any security. News and coverage analytics are drawn from the 4Search index. Terms of use. How to use Finance